Fortis Memorial Research Institute (FMRI), Gurugram, in collaboration with Agilus Diagnostics, has launched its second Genexus system, further strengthening India's fastest and most scalable rapid genomic testing program. This milestone reflects Fortis’ and Agilus’ shared focus on improving cancer care through timely, precise diagnostics and targeted treatment decisions.

The Genexus platform enables Next-Generation Sequencing (NGS) with significantly faster turnaround times—delivering Liquid Biopsy results in 24 hours, Myeloid NGS in 72 hours, and MRD testing within five days. This is a major improvement over traditional diagnostics, which often take weeks.

“With the addition of the second Genexus system, we can now expand our rapid NGS workflow for AML and other hematologic malignancies across more patients and regions,” said Dr. Rahul Bhargava, Principal Director and Chief – Haematology and Bone Marrow Transplant, FMRI. “Genomics is now an essential part of cancer treatment. Faster, deeper insights mean better treatment decisions and a better chance at survival.”

Dr. Anand K, MD & CEO, Agilus Diagnostics, said: “With the second Genexus system, we’re better positioned to expand access to advanced molecular diagnostics and deliver actionable insights faster. This is a crucial step toward personalized medicine for Indian cancer patients.”

Backed by Fortis’ clinical expertise and Agilus’ national lab network, the program brings together haematologists, oncologists, molecular pathologists, and bioinformaticians under one roof. As Fortis and Agilus accelerate the rollout of AI-enabled genomics and integrated tumour boards, this expansion marks a significant advance in precision oncology in India.